

April 27, 2020



## Rigel Announces Conference Call and Webcast to Report First Quarter 2020 Financial Results and Business Update

SOUTH SAN FRANCISCO, Calif., April 27, 2020 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that it will report its first quarter 2020 financial results after market close on Tuesday, May 5, 2020. Rigel senior management will follow the announcement with a live conference call and webcast at 4:30pm Eastern Time (1:30pm Pacific Time) to discuss the financial results and give an update on the business.

Participants can access the live conference call by dialing (877) 407-3088 (domestic) or (201) 389-0927 (international). The conference call and accompanying slides will also be webcast live and can be accessed from the Investor Relations section of the company's website at [www.rigel.com](http://www.rigel.com). The webcast will be archived and available for replay for 90 days after the call via the Rigel website.

### **About Rigel ([www.rigel.com](http://www.rigel.com))**

Rigel Pharmaceuticals, Inc., is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. Rigel's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA approved product is TAVALISSE<sup>®</sup> (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The product has been approved by the European Commission for the treatment of chronic immune thrombocytopenia in adult patients who are refractory to other treatments, and will be marketed in Europe under the name TAVLESSE<sup>™</sup> (fostamatinib).

Rigel's clinical programs include a Phase 3 study of fostamatinib in warm autoimmune hemolytic anemia (AIHA); a completed Phase 1 study of R835<sup>1</sup>, a proprietary molecule from its interleukin receptor associated kinase (IRAK) inhibitor program; and an ongoing Phase 1 study of R552<sup>1</sup>, a proprietary molecule from its receptor-interacting protein kinase (RIP) inhibitor program. In addition, Rigel has product candidates in clinical development with partners Aclaris Therapeutics, AstraZeneca, BerGenBio ASA, and Daiichi Sankyo.

**Please see [www.TAVALISSE.com](http://www.TAVALISSE.com) for the full Prescribing Information.**

<sup>1</sup>The product for this use or indication is investigational and has not been proven safe or effective by any regulatory authority.

Contact: David Burke

Phone: 650.624.1232

Email: [dburke@rigel.com](mailto:dburke@rigel.com)



View original content to download multimedia <http://www.prnewswire.com/news-releases/rigel-announces-conference-call-and-webcast-to-report-first-quarter-2020-financial-results-and-business-update-301047309.html>

SOURCE Rigel Pharmaceuticals, Inc.